In response to the continued efforts to address the ongoing drug shortage crisis, the US Association for Accessible Medicines has commended the country’s Federal Trade Commission and Department of Health and Human Services for their latest bid to “uncover the root causes and potential solutions to drug shortages.”
AAM Applauds FTC-HHS Probe Into Generic Drug Shortages
The Inquiry Will Focus On GPOs and Drug Wholesalers
As two US governmental agencies launch an investigation into the potential causes of drug shortages, AAM says the generics industry faces “unprecedented threats.”
More from Generics
More from Products
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.